5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Thulium Fiber Laser: Bringing Lasers to a Whole New Level

      discussion
      a , b , * , a
      European Urology Open Science
      Elsevier

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Over the past few years, numerous trials have supported the fact that endoscopic enucleation of the prostate (EEP) is both safe and efficient, whether its compared to transurethral resection of the prostate (TURP) or other laser-based techniques (eg, photovaporization of the prostate) [1], [2]. The international guidelines consider EEP to be one of the techniques of choice for relief of benign prostatic obstruction (BPO). Most of the data on EEP support the fact that irrespective of which device is used, the efficacy of EEP will remain the same. Despite all this evidence, the discussion regarding which instrument is best to use is ongoing. A recent systematic review by Pallauf et al. [1] suggests that different energy sources are similarly effective and would have a different effect on the intervention itself. Thus, is the jury still out on which is actually the best laser for the job? The most recent addition to the pool of lasers—thulium fiber laser (TFL)—could potentially be considered at some point “the best device for EEP”. In this short piece, we look at TFL from three major points: first, in the context of the evolution of lasers; second, as a device with unique physical properties; and third, as a laser that has great surgical potential and offers new promises and opportunities. Ho:YAG, which was not fully recognized in BPO surgery when it was first introduced to the field, took the leading position in just a few years after Gilling et al. [3] developed the holmium laser enucleation of the prostate (HoLEP) technique. A few years after this development, Gilling et al presented the first results from a randomized trial comparing TURP and HoLEP, showing shorter catheter time and more durable BPO relief (according to urodynamics). However, despite the obvious advances, a few technical limitations remained. These included the long learning curve and the complexity of holmium enucleation for inexperienced surgeons [4]. This has prompted researchers to search for an instrument that is superior to Ho:YAG [5]. The introduction of Tm:YAG laser to endourology represented a great leap forward. As a continuous wave device, it has a better water absorption coefficient (eg, 52 cm−1 for Tm:YAG and 26 cm−1 for Ho:YAG, resulting in a shallower theoretical penetration depth of 0.2 mm vs 0.4–0.7 mm). As a continuous-wave device, Tm:YAG is also able to effectively coagulate tissues; in a perfused porcine kidney model, Tm:YAG showed a minimal bleeding rate of 0.16 ± 0.07 g/min in comparison to 20.14 g/min with TURP (p < 0.05) [6]. Despite its superior cutting and coagulation, Tm:YAG still has a number of limitations, such as a tendency for greater vaporization and prominent carbonization [7]. Further introduction of TFL in endourology took into consideration the advantages and drawbacks of Tm:YAG. The first tests completed using low-power TFL showed that it is an effective cutting tool with high potential for hemostasis [8]. This is possible because TFL has a better absorption coefficient in water (114 cm−1, which is twofold better than for Tm:YAG and fourfold better than for Ho:YAG). This allows a reduction in the theoretical penetration depth to a minimal 0.15 mm. Moreover, while Ho:YAG incision is characterized by ruptured and uneven edges on pathology (owing to the higher peak power of Ho:YAG), TFL tends to result in clearer and shallower cuts [9], [10]. However, the dramatic improvement in penetration depth with TFL is not the only advantage of this device. The real TFL secret is in its medium, which is the most important component of each laser device. The most frequently used lasers are Ho:YAG and Tm:YAG (solid-state lasers), which are based on a medium made from a solid yttrium aluminum garnet (YAG) crystal. TFL is different in that the medium is made from woven silica fiber that is chemically doped with thulium ions. This construction means that TFL devices are much smaller then Ho:YAG and Tm:YAG and prevents extensive heating; an air cooling system is sufficient for TFL, in contrast to the water cooling systems required for Ho:YAG and Tm:YAG [11]. However, this is not the only advantage: solid-state lasers use flash lamps as the energy source for the firing, while TFL uses small diodes. This allows TFL to work in two modes, superpulse mode for stones and quasicontinuous mode (QCW) for soft tissues. Ex vivo studies have shown that QCW TFL produces coniform ablation zones (2.7 ± 0.3 mm vs 1.6 ± 0.2 mm with Ho:YAG) with a rounded apex surrounded by a marked coagulation zone (up to 0.6 ± 0.2 mm vs 0.1 ± 0.1 mm with Ho:YAG). While the pulsed firing of Ho:YAG may lead to significant tissue rupture, TFL cuts showed clear edges with no ruptures. It also did not lead to extensive tissue carbonization, although any carbonization observed was more pronounced than with Ho:YAG [10]. The authors hypothesized that this result is likely to translate into superior cutting and coagulation abilities in clinical practice. Considering the above-mentioned advantages, the question arises as to how they influence surgery. EEP is an energy-independent technique that results in acceptable results in terms of intraoperative safety, functional outcomes, and complications when compared to Ho:YAG, and Tm:YAG laser energy sources, among others [12], [13]. The first clinical results show that TFL is pushing ahead of TURP and open simple prostatectomy (lower rate of bleeding and shorter catheterization time and hospital stay) [14], [15]. In comparison to Ho:YAG, no advantages in terms of efficiency or safety were observed [16]. A recent randomized trial of HoLEP and TFL laser enucleation of the prostate (ThuFLEP) revealed that the deeper ablation and coagulation zones with TFL do not translate into higher rates of urinary incontinence and irritation after surgery (assessed with QUID, ICIQ-MLUTS) [17]. Despite a comparable bleeding rate in these trials, TFL, owing to its better coagulation ability, should still be promising in terms of lower bleeding rates and faster hemostasis, which was confirmed in ex vivo tests [11]. Another advantage is a shorter learning curve, as previously demonstrated. The ablation rate with ThuFLEP in the hands of trainees was higher than with monopolar enucleation (p < 0.001) with a slight advantage over HoLEP (1.0 vs 0.8 g/min; p = 0.07). The trainees mentioned that the low carbonization made ThuFLEP more convenient for them in comparison to monopolar surgery, whereas efficient tissue cutting allowed them to easily restore the enucleation plane when compared to HoLEP. However, this is difficult to assess objectively and is mostly based on surgeons’ opinions [18]. As mentioned previously, TFL does not use flash lamps or water cooling, relying instead on a diode laser as source and air cooling. Thus, as a high-power machine, TFL uses a standard power outlet and has significantly lower noise in comparison to Ho:YAG [11]. Moreover, this may also increase the cost effectiveness of the device, as the diode laser used as a source has a longer lifespan than a flash lamp and the air-cooling system does not require coolant replacement [19]. However, all these statements need to be confirmed in subsequent trials. To sum up, the technique of prostate enucleation itself might level out the disadvantages of the instrument used. Thus, if you are thinking about treating BPO, use EEP. Nevertheless, if you are looking for a universal instrument that has already proved itself to be effective as a solid-state device (Ho:YAG and Tm:YAG) and that has better physical properties, greater cost efficiency, and superior adaptation, then choose TFL. 

 Conflicts of interest : The authors have nothing to disclose.

          Related collections

          Most cited references18

          • Record: found
          • Abstract: found
          • Article: not found

          High-power thulium fiber laser ablation of urinary tissues at 1.94 microm.

          This paper describes the preliminary testing of a new laser, the thulium fiber laser, as a potential replacement for the holmium:YAG laser for multiple applications in urology. A 40 W thulium fiber laser operating at a wavelength of 1.94 microm delivered radiation in a continuous-wave or pulsed mode (10 msec) through either 300-microm- or 600-microm-core low-OH silica fibers for vaporization of canine prostate and incision of animal ureter and bladder-neck tissues. The thulium fiber laser vaporized prostate tissue at a rate of 0.21+/-0.02 g/min. The thermal-coagulation zone measured 500 to 2000 microm, demonstrating the potential for hemostasis. Laser incisions were also made in bladder tissue and ureter, with coagulation zones of 400 to 600 microm. The thulium fiber laser has several potential advantages over the holmium laser, including smaller size, more efficient operation, more precise incision of tissues, and operation in either the pulsed or the continuous-wave mode. However, before clinical use will be possible, development of higher-power thulium fiber lasers and shorter pulse lengths will be necessary for rapid vaporization of the prostate and more precise incision of urethral/bladder-neck strictures, respectively.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The laser of the future: reality and expectations about the new thulium fiber laser—a systematic review

            The Holmium:yttrium-aluminum-garnet (Ho:YAG) laser has been the gold-standard for laser lithotripsy over the last 20 years. However, recent reports about a new prototype thulium fiber laser (TFL) lithotripter have revealed impressive levels of performance. We therefore decided to systematically review the reality and expectations for this new TFL technology. This review was registered in the PROSPERO registry (CRD42019128695). A PubMed search was performed for papers including specific terms relevant to this systematic review published between the years 2015 and 2019, including already accepted but not yet published papers. Additionally, the medical sections of ScienceDirect, Wiley, SpringerLink, Mary Ann Liebert publishers, and Google Scholar were also searched for peer-reviewed abstract presentations. All relevant studies and data identified in the bibliographic search were selected, categorized, and summarized. The authors adhered to PRISMA guidelines for this review. The TFL emits laser radiation at a wavelength of 1,940 nm, and has an optical penetration depth in water about four-times shorter than the Ho:YAG laser. This results in four-times lower stone ablation thresholds, as well as lower tissue ablation thresholds. As the TFL uses electronically-modulated laser diodes, it offers the most comprehensive and flexible range of laser parameters among laser lithotripters, with pulse frequencies up to 2,200 Hz, very low to very high pulse energies (0.005–6 J), short to very long-pulse durations (200 µs up to 12 ms), and a total power level up to 55 W. The stone ablation efficiency is up to four-times that of the Ho:YAG laser for similar laser parameters, with associated implications for speed and operating time. When using dusting settings, the TFL outperforms the Ho:YAG laser in dust quantity and quality, producing much finer particles. Retropulsion is also significantly reduced and sometimes even absent with the TFL. The TFL can use small laser fibers (as small as 50 µm core), with resulting advantages in irrigation, scope deflection, retropulsion reduction, and (in)direct effects on accessibility, visibility, efficiency, and surgical time, as well as offering future miniaturization possibilities. Similar to the Ho:YAG laser, the TFL can also be used for soft tissue applications such as prostate enucleation (ThuFLEP). The TFL machine itself is seven times smaller and eight times lighter than a high-power Ho:YAG laser system, and consumes nine times less energy. Maintenance is expected to be very low due to the durability of its components. The safety profile is also better in many aspects, i.e., for patients, instruments, and surgeons. The advantages of the TFL over the Ho:YAG laser are simply too extensive to be ignored. The TFL appears to be a real alternative to the Ho:YAG laser and become a true game-changer in laser lithotripsy. Due to its novelty, further studies are needed to broaden our understanding of the TFL, and comprehend the full implications and benefits of this new technology, as well its limitations.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              EAU guidelines on laser technologies.

              The European Association of Urology (EAU) Guidelines Office has set up a guideline working panel to analyse the scientific evidence published in the world literature on lasers in urologic practice. Review the physical background and physiologic and technical aspects of the use of lasers in urology, as well as current clinical results from these new and evolving technologies, together with recommendations for the application of lasers in urology. The primary objective of this structured presentation of the current evidence base in this area is to assist clinicians in making informed choices regarding the use of lasers in their practice. Structured literature searches using an expert consultant were designed for each section of this document. Searches were carried out in the Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials, and Medline and Embase on the Dialog/DataStar platform. The controlled terminology of the respective databases was used, and both Medical Subject Headings and EMTREE were analysed for relevant entry terms. One Cochrane review was identified. Depending on the date of publication, the evidence for different laser treatments is heterogeneous. The available evidence allows treatments to be classified as safe alternatives for the treatment of bladder outlet obstruction in different clinical scenarios, such as refractory urinary retention, anticoagulation, and antiplatelet medication. Laser treatment for bladder cancer should only be used in a clinical trial setting or for patients who are not suitable for conventional treatment due to comorbidities or other complications. For the treatment of urinary stones and retrograde endoureterotomy, lasers provide a standard tool to augment the endourologic procedure. In benign prostatic obstruction (BPO), laser vaporisation, resection, or enucleation are alternative treatment options. The standard treatment for BPO remains transurethral resection of the prostate for small to moderate size prostates and open prostatectomy for large prostates. Laser energy is an optimal treatment method for disintegrating urinary stones. The use of lasers to treat bladder tumours and in laparoscopy remains investigational. Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                Journal
                Eur Urol Open Sci
                Eur Urol Open Sci
                European Urology Open Science
                Elsevier
                2666-1691
                2666-1683
                20 December 2022
                February 2023
                20 December 2022
                : 48
                : 31-33
                Affiliations
                [a ]Department of Urology, Medical University of Vienna, Vienna, Austria
                [b ]Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
                Author notes
                [* ]Corresponding author. Department of Urology, Medical University of Vienna, Vienna, Austria. Tel. +7 925 5177926. dvenikeev@ 123456gmail.com
                Article
                S2666-1683(22)00748-0
                10.1016/j.euros.2022.07.007
                9795521
                36588770
                511fc30b-dfe7-4fe3-9e0a-42366fd4b6f3
                © 2022 The Author(s)

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 21 July 2022
                Categories
                Open to Debate: For

                Comments

                Comment on this article